ZERVIATE
Peakcetirizine
NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
May 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Histamine H1 Receptor Antagonists
Pharmacologic Class:
Histamine-1 Receptor Antagonist
Clinical Trials (5)
Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine
Started Mar 2020
34 enrolled
Oncology Patients Receiving Chemotherapy
Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab
Started Feb 2020
19 enrolled
Multiple SclerosisInfusion Reaction
Cetirizine Chewable Bioequivalence and Food Effect Study
Started Dec 2018
40 enrolled
Allergy
Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT)
Started May 2018
72 enrolled
Rhinitis
The Effect of Cetirizine on Bronchoconstriction
Started May 2018
Loss of Exclusivity
LOE Date
Jan 9, 2033
83 months away
Patent Expiry
Jan 9, 2033
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8829005 | Mar 15, 2030 | U-1680 | |
| 9750684 | Mar 15, 2030 | Product | — |
| 9993471 | Mar 15, 2030 | U-1680 | |
| 8829005*PED | Sep 15, 2030 | — | |
| 9254286 | Jul 9, 2032 | Product | — |